Diflunisal treatment is associated with improved survival for patients with early stage wild-type transthyretin (ATTR) amyloid cardiomyopathy: the Boston University Amyloidosis Center experience.

ABSTRACT:

Background

Diflunisal is a non-steroidal anti-inflammatory drug that stabilises transthyretin (TTR) and reduces neurologic deterioration in patients with polyneuropathy caused by hereditary transthyretin amyloidosis (ATTRv).

Methods

We conducted a retrospective cohort study of patients with wild-type transthyretin cardiac amyloidosis (ATTRwt-CM) treated with diflunisal for at least one year between 2009 and 2016 at the Boston University Amyloidosis Centre. Baseline and one year follow up characteristics were measured, including plasma chemistries and echocardiography. Cox proportional hazards analysis assessed the primary outcome of all-cause mortality.

Results

A total of 104 ATTRwt-CM patients were evaluated with 35 patients receiving diflunisal. Patients in the difl

SUBMITTER: Siddiqi OK 

PROVIDER: S-EPMC9258521 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature